Mental Health and Behavioral Sciences, Defense and Veterans Brain Injury Center, James A. Haley Veterans' Hospital, Morsani College of Medicine, Division of Pulmonary and Sleep Medicine, University of South Florida, Tampa, FL.
Medicine Service, James A. Haley Veterans' Hospital, Morsani College of Medicine, Division of Pulmonary and Sleep Medicine, University of South Florida, Tampa, FL.
Chest. 2020 Oct;158(4):1689-1700. doi: 10.1016/j.chest.2020.03.083. Epub 2020 May 6.
OSA is prevalent during a time of critical neural repair after traumatic brain injury (TBI). The diagnostic utility of existing sleep studies is needed to inform clinical management during acute recovery from TBI.
This study aimed to evaluate the non-inferiority and diagnostic accuracy of a portable level 3 sleep study relative to level 1 polysomnography in hospitalized neurorehabilitation patients with TBI.
This is a prospective clinical trial conducted at six TBI Model System study sites between May 2017 and February 2019. Of 896 admissions, 449 were screened and eligible for the trial, with 345 consented. Additional screening left 263 eligible for and completing simultaneous administration of both level 1 and level 3 sleep studies, with final analyses completed on 214 (median age = 42 years; ED Glasgow Coma Scale = 6; time to polysomnography [PSG] = 52 days).
Agreement was moderate to strong (weighted kappa = 0.78, 95% CI, 0.72-0.83) with the misclassification commonly occurring with mild sleep apnea due to underestimation of apnea hypopnea index (AHI). Most of those with moderate to severe sleep apnea were correctly classified (n = 54/72). Non-inferiority was not demonstrated: the minimum tolerable specificity of 0.5 was achieved across all AHI cutoff scores (lower confidence limits [LCL] range, 0.807-0.943), but the minimum tolerable sensitivity of 0.8 was not (LCL range, 0.665-0.764).
Although the non-inferiority of level 3 portable diagnostic testing relative to level 1 was not established, strong agreement was seen across sleep apnea indexes. Most of those with moderate to severe sleep apnea were correctly identified; however, there was risk of misclassification with level 3 sleep studies underestimating disease severity for those with moderate to severe AHI and disease presence for those with mild AHI during early TBI neurorehabilitation.
阻塞性睡眠呼吸暂停(OSA)在创伤性脑损伤(TBI)后神经修复的关键时期普遍存在。需要了解现有的睡眠研究对 TBI 急性恢复期的临床管理有何诊断价值。
本研究旨在评估便携式 3 级睡眠研究相对于 1 级多导睡眠图在 TBI 神经康复住院患者中的非劣效性和诊断准确性。
这是一项于 2017 年 5 月至 2019 年 2 月在六个 TBI 模型系统研究点进行的前瞻性临床试验。在 896 例入院患者中,对 449 例进行了筛查并符合试验条件,其中 345 例同意入组。进一步的筛查后,263 例患者同时进行了 1 级和 3 级睡眠研究,最终分析了 214 例(中位年龄 42 岁;急诊格拉斯哥昏迷量表 [GCS] 评分为 6;多导睡眠图 [PSG] 时间为 52 天)。
一致性为中度至高度(加权 Kappa=0.78,95%置信区间,0.72-0.83),轻度睡眠呼吸暂停由于呼吸暂停低通气指数(AHI)低估导致轻度睡眠呼吸暂停的分类错误较为常见。大多数中度至重度睡眠呼吸暂停患者得到了正确分类(n=54/72)。未能证明非劣效性:在所有 AHI 截止分数下,最低可接受的特异性为 0.5(置信下限 [LCL] 范围为 0.807-0.943),但最低可接受的敏感性为 0.8 未达到(LCL 范围为 0.665-0.764)。
尽管 3 级便携式诊断测试相对于 1 级的非劣效性没有得到证实,但在所有睡眠呼吸暂停指标上都有强烈的一致性。大多数中度至重度睡眠呼吸暂停患者得到了正确识别;然而,对于中度至重度 AHI 的患者,3 级睡眠研究可能低估疾病严重程度,对于轻度 AHI 的患者可能低估疾病存在,存在分类错误的风险。